GET DAILY SIGNALSClarivate (CLVT): Can the Stock Reach the $2.80 Analyst Target?
Key Takeaways
- The central target of $2.80 is the arithmetic mean of six current, individually verified analyst price targets, rounded from a calculated mean of about $2.77.
- The analyst range is unusually wide, from a low of $1.50 (Morgan Stanley) to a high of $5.00 (Stifel), reflecting sharp disagreement about the company's turnaround.
- At the latest verified price of about $1.66, reaching $2.80 would require a gain of roughly 69%—a very large move by any standard.
- The strongest supporting factor is Clarivate's free cash flow and portfolio restructuring, including the divestiture of its Life Sciences & Healthcare segment.
- The biggest risks are sustained organic revenue declines, artificial intelligence-driven disintermediation, and elevated leverage.
- You can dig deeper into Clarivate's Major News, Today's Price Move, Forecast, and Earnings on dedicated analysis pages.
- For automated, data-driven market screening, explore Trending AI Robots.
Analyst Price Targets and Consensus View
Six current, attributable analyst price targets were reviewed to establish the central target. The individual targets are: Morgan Stanley at $1.50 (Underweight, late October 2026), Barclays at $2.00 (Underweight), Citi at $2.50 (Neutral), Goldman Sachs at $2.60 (Neutral), RBC Capital at $3.00 (Sector Perform), and Stifel at $5.00 (Buy). The calculated arithmetic mean is approximately $2.77, rounded to a clean $2.80.
The range of $1.50 to $5.00 is exceptionally wide, which signals genuine disagreement rather than a uniform consensus. Only one of the six firms carries a bullish rating, while two are outright bearish and three are neutral. Notably, most firms trimmed their targets on July 30, 2026 after second-quarter results, and Morgan Stanley resumed coverage with a cautious $1.50 target in late October 2026. The average analyst price target is best read as a reference point, not a forecast of where the stock will trade. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
With the latest verified price near $1.66, the move to $2.80 represents roughly 69% upside—a very large move. Clarivate's market capitalization has contracted to roughly $1.06 billion, while trailing-twelve-month revenue stands near $2.41 billion and the company has posted a net loss of about $334 million over that period. The forward P/E (price-to-earnings ratio) is compressed at roughly 2.4 times adjusted earnings, but total debt of about $4.26 billion keeps the enterprise value near $5.1 billion, well above the equity value.
A path toward $2.80 would likely require a combination of stabilizing organic revenue, successful execution of the company's "Value Creation Plan," and a meaningful re-rating of the shares. Given the stock's 52-week range of about $1.42 to $3.87, a return toward the $2.80 area would still sit below the prior-year high.
What Could Support a Move Toward the Target
Clarivate's most defensible attribute is cash generation, with levered free cash flow near $465 million over the past twelve months. The company has used buybacks to reduce its share count, and it is simplifying its portfolio—including a divestiture of the Life Sciences & Healthcare segment for roughly $600 million to Altaris. If that transaction reduces leverage and sharpens focus on core IP and academic data franchises, it could support a higher valuation.
Bullish analysts, led by Stifel's $5.00 target, argue the shares are inexpensive on free cash flow and that the reset expectations leave room for upside if organic growth inflects. A stabilization of subscription revenue and successful rollout of AI-enabled products such as Web of Science Research Intelligence are key swing factors.
What Could Prevent the Target From Being Reached
The bearish case is substantial. Revenue has been declining, with trailing-twelve-month revenue down roughly 3.5% year over year, and analysts broadly expect further contraction. The more cautious firms—Morgan Stanley and Barclays—cite modest organic growth, pricing-power limits, and execution risk. Artificial intelligence is a genuine threat, as cheaper generative-AI tools can substitute for parts of Clarivate's information and workflow products.
Elevated debt relative to equity, persistent net losses, and high short interest of roughly 7% of shares outstanding all add pressure. If organic revenue keeps shrinking or the restructuring fails to improve margins, the shares could remain anchored near current levels or lower.
Technical Levels and Market Structure
Clarivate trades below both its 50-day moving average near $1.81 and its 200-day moving average near $2.22, keeping the near-term trend tilted lower. The 52-week range of roughly $1.42 to $3.87 makes $1.42 an important support level, while $2.20 to $2.30—the area of the 200-day average—is an initial resistance zone that would need to be reclaimed before the $2.80 target becomes relevant. Round-number levels around $2.00 and $2.50 may also act as psychological markers.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms may differ. Investors should watch upcoming quarterly results, any guidance on organic revenue and free cash flow, further analyst target revisions, progress on the portfolio divestitures and deleveraging, and the competitive impact of AI on subscription demand. Changes in the share count through buybacks and any shift in short interest are also worth monitoring.
Exploring AI Daily Buy/Sell Signals
In my research process, I frequently review Tickeron's AI Daily Buy/Sell Signals to get a systematic view of market movements. This tool applies artificial intelligence to monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on technical behavior and changing conditions. It helps me spot shifts more efficiently and complements the fundamental analysis of names like Clarivate.
Final Assessment
The $2.80 central target is a calculated average of six analyst price targets spanning a very wide $1.50 to $5.00 range. Reaching it would require a gain of roughly 69% from current levels—a very large move that hinges on a fundamental turnaround Clarivate has not yet delivered. The bull case rests on free cash flow, deleveraging, and a potential re-rating; the bear case points to declining revenue, AI disintermediation, and execution risk. With only one bullish rating among the group and most firms holding neutral or cautious stances, the path to $2.80 depends heavily on evidence of stabilized organic growth and successful restructuring. Investors should monitor quarterly results and analyst revisions closely rather than treat the average target as a foregone conclusion.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for CLVT turns negative, indicating new downward trend
CLVT saw its Momentum Indicator move below the 0 level on October 29, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned negative. In 77 of the 84 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
CLVT moved below its 50-day moving average on October 27, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLVT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for CLVT entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CLVT's RSI Oscillator exited the oversold zone, 32 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for CLVT just turned positive on October 13, 2026. Looking at past instances where CLVT's MACD turned positive, the stock continued to rise in 37 of 46 cases over the following month. The odds of a continued upward trend are 80%.
Following a +6.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLVT advanced for three days, in 161 of 245 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
CLVT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.234) is normal, around the industry mean (2.802). P/E Ratio (-3.192) is within average values for comparable stocks, (18.164). Projected Growth (PEG Ratio) (0.178) is also within normal values, averaging (2.284). Dividend Yield (0.000) settles around the average of (0.195) among similar stocks. P/S Ratio (0.504) is also within normal values, averaging (139.965).
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. CLVT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLVT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What is a Life Estate?
What is the essence of Trickle-Down Economics, and how does it function in practice?
Asset Acquisition: Top Market Leaders
What Are the 6 Essential Books for Becoming a Successful Options Trader?
Why NVIDIA May Lose China Sales but Win the AI Battle: Short and Long Term Considerations
General Information
a maker of activated carbon and related products and systems
Industry InformationTechnologyServices
Advertisement